Score Overview
Explore the 2021 public Archive ranking →
Where TG Therapeutics Inc has ranked, year by year
Showing 20 years ranking history by Net Income Growth.
Has not reached the top 50 on Net Income Growth in any year we have ranked.
- TGTX
2017: 97.8% · 2021: 98.3% · free through 2021 · longest runs
Net Income x Stock Price
Historical Returns
| Period | Price | Return |
|---|---|---|
Last Price2026-09-30 | $ 55.78 | — |
1 Year2025-09-30 | $ 36.13 | 54.41% |
5 Years2021-09-30 | $ 33.28 | 67.61% |
10 Years2016-09-30 | $ 7.74 | 7x |
| Period | Last Price2026-09-30 | 1 Year2025-09-30 | 5 Years2021-09-30 | 10 Years2016-09-30 |
|---|---|---|---|---|
| Price | $ 55.78 | $ 36.13 | $ 33.28 | $ 7.74 |
| Return | — | 54.41% | 67.61% | 7x |
Prices are split & dividend adjusted. All values are reported in USD.
Fundamental Data
Reported in USD
| Year | |||
|---|---|---|---|
| TTM | $ 799M | $ 441M | $ 552M |
| 2025 | $ 616M | $ 447M | $ 141M |
| 2024 | $ 329M | $ 23M | $ 311M |
| 2023 | $ 233M | $ 12M | $ 217M |
| 2022 | $ 2M | -$ 223M | $ 161M |
| 2021 | $ 6M | -$ 348M | $ 314M |
| 2020 | $ 152K | -$ 279M | $ 605M |
| 2019 | $ 152K | -$ 172M | $ 140M |
| 2018 | $ 152K | -$ 173M | $ 68M |
| 2017 | $ 152.38K | -$ 118M | $ 84M |
| 2016 | $ 152.38K | -$ 78M | $ 44M |
| 2015 | $ 152.38K | -$ 62M | $ 102M |
| 2014 | $ 152.38K | -$ 55M | $ 78M |
| 2013 | $ 152.38K | -$ 20M | $ 45M |
| 2012 | $ 19.05K | -$ 18M | $ 16M |
| 2011 | $ 0.00 | -$ 853.07K | $ 9M |
| 2010 | $ 623.64K | $ 478.67K | |
| 2009 | -$ 2M | $ 18K | |
| 2008 | -$ 4M | $ 106.02K | |
| 2007 | -$ 12M | $ 649.69K | |
| 2006 | -$ 9M | $ 3M | |
| 2005 | -$ 19M | $ 10M | |
| 2004 | -$ 5M | $ 5M | |
| 2003 | -$ 5M | $ 7M | |
| 2002 | $ 500K | -$ 1M | $ 116.29K |
| 2001 | $ 2M | -$ 1M | $ 1M |
| 2000 | $ 5M | -$ 5M | $ 2M |
| 1999 | $ 1M | -$ 2M | $ 3M |
| 1998 | $ 3M | -$ 2M | $ 5M |
| 1997 | $ 100K | -$ 5M | $ 8M |
| 1996 | $ 100K | -$ 3M | $ 2M |
TG Therapeutics Inc fundamental performance
Between 2020 and 2025, revenue grew from $ 152K to $ 616M and net income went from -$ 279M to $ 447M. Revenue increased in 4 of those 5 years; net income in 4.
Across TG Therapeutics Inc's full reported history, from 1996 to 2025, revenue grew from $ 100K to $ 616M and net income went from -$ 3M to $ 447M. Revenue increased in 43% of the years measured; net income in 47%.
TG Therapeutics Inc currently holds a 5-year HDB Score of 8.1 out of 10. How the HDB Score is calculated.
Membership
Continue TGTX’s history
The public Archive runs through 2021. Membership adds recent and current rankings.
- Recent and current rankings across 3,814 companies
- Compare companies with the latest data
- Track your research shortlist in a portfolio
